Ginkgo Bioworks Holdings Inc (NYSE:DNA) finished Thursday with a subtraction of -$0.06 to close at $1.72, a downside of -3.37 percent. An average of 20,001,820 shares of common stock have been traded in the last five days. There was a fall of -$0.0300 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 19,855,150 shares traded, while the 50-day average volume stands at 20,950,990.
DNA stock has decreased by -22.52% in the last month. The company shares reached their 1-month lowest point of $1.7000 on 09/28/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $1.12 and a high of $3.52 in 52 weeks. It has reached a new high 9 times so far this year and achieved 1.78% or $0.0300 in price. In spite of this, the price is down -51.14% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DNA stock investors should be aware that Ginkgo Bioworks Holdings Inc (DNA) stock had its last reported insider trading activity 8 days ago on Sep 21. In this transaction, the insider spent $176,600. 10% Owner, Canton Barry, disposed of 37,650 shares at a price of $1.76 on Sep 21. The insider now owns more than $66,452 worth of shares. Prior to that, Shetty Reshma P. went on to Sale 37,650 shares at $1.76 each on Sep 21. An amount of $66,452 was transacted.
Valuation Metrics
Ginkgo Bioworks Holdings Inc (DNA) stock’s beta is 1.27. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 10.44, the price-to-book (PB) ratio at 2.10.
Financial Health
The quick ratio of Ginkgo Bioworks Holdings Inc for the three months ended June 29 was 7.49, and the current ratio was 7.49, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.27 and a total debt to equity ratio of 0.27 for the quarter ending June 29. Its gross profit as reported stood at $273.49 million compared to revenue of $477.71 million.
Earnings Surprise
The analyst consensus anticipated Ginkgo Bioworks Holdings Inc’s latest quarter earnings to come in at -$0.08 per share, but it turned out to be -$0.09, a -12.50% surprise. For the quarter, EBITDA amounted to -$165.93 million. Shareholders own equity worth $1.98 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Ginkgo Bioworks Holdings Inc (DNA) price momentum. RSI 9-day as of the close on 28 September was 32.27%, suggesting the stock is Neutral, with historical volatility in this time frame at 36.89%.
As of today, DNA’s price is $1.7460 -1.71% or -$0.0300 from its 5-day moving average. DNA is currently trading -23.56% lower than its 20-day SMA and +35.43% higher than its 100-day SMA. However, the stock’s current price level is -32.28% below the SMA50 and -5.49% below the SMA200.
The stochastic %K and %D were 7.88% and 6.69%, respectively, and the average true range (ATR) was 0.1301. With the 14-day stochastic at 4.26% and the average true range at 0.1342, the RSI (14) stands at 38.10%. The stock has reached -0.0322 on the 9-day MACD Oscillator while the 14-day reading was at -0.1174.
Analyst Ratings
Goldman downgraded Ginkgo Bioworks Holdings Inc (NYSE: DNA) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Ginkgo Bioworks Holdings Inc (DNA) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell DNA, while 2 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 4 others rate it as a “buy”.
What is DNA’s price target for the next 12 months?
Analysts predict a range of price targets between $1.25 and $12.00, with a median target of $3.20. Taking a look at these predictions, the average price target given by analysts for Ginkgo Bioworks Holdings Inc (DNA) stock is $4.02.
